Migraine with aura has been associated with cardiovascular disease (CVD), in particular with ischemic stroke (1) ; however, such an association has not been consistently shown for CVD mortality (2) . Rossi et al. (3) have reinvestigated data from observational studies on the association between migraine and mortality as summarized in our meta-analysis (2) . Specifically, they have addressed the question of whether there is a time trend for the risk of CVD mortality by performing a meta-regression with the relative risk as the dependent variable and the publication date as the independent variable. They report a suggestive trend towards increased CVD mortality over time (p ¼ 0.054).
In general, when assessing time trends, the first step involves identifying the observation of interest (here mortality) by an appropriate time period. This has three important implications. First, the concept of an appropriate time period means that the population should be under observation during the time period under question. Second, the time period of observation should be of reasonable duration. Although very short time windows may be suitable for post-operative outcomes (4,5), for other outcomes this may not be appropriate, as the number of events may be too few to calculate a reliable risk estimate. For studies investigating the association between migraine and mortality long-term follow-up is needed. Finally, the observation periods among the studies should be of similar length in order to be comparable.
With respect to the studies investigating the association between migraine and mortality (2), the following aspects need to be considered. Rossi et al. (3) have chosen the date of publication as a proxy for the observation period. However, the time periods from end of observation until publication vary between 2 and 5 years. Further, the observation periods among the studies vary considerably ranging from an average of 1.4 to 25.9 years, with three of the studies spanning observation times 10 years (2). Hence, time trends within these observation periods are undetectable when considering summary risk estimates. Further, slicing long observation periods into periods of equal length may improve comparability; however, this may interfere with the ability to accurately assess the risk estimate.
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